AUA 2024: Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
AUA 2024 third interim analysis of the DARolutamide ObservationaL (DAROL) study, nonmetastatic castration-resistant prostate cancer (nmCRPC), DAROL study, darolutamide, phase 3 ARAMIS trial.